resolvin-d1 and Endometriosis

To study the effects of two resolvins of D series, RvD1 and 17(R)-RvD1, on inflammatory signs associated with endometriosis (ENDO).. In vivo research study.. Research laboratory.. Female Sprague-Dawley rats.. Intravenous or intraperitoneal injections of RvD1 (300 ng/kg) or 17(R)-RvD1 (300 and 900 ng/kg) in rats with surgically induced ENDO.. Vascular permeability of ectopic endometrial growths was assessed by Evans Blue extravasation; vaginal hyperalgesia was assessed with telemetered visceromotor response.. Both resolvins, but not vehicle, significantly decreased vascular permeability in ectopic endometrial tissue. 17(R)-RvD1 also significantly alleviated severity of vaginal hyperalgesia.. Our results suggest that RvD1 and 17(R)-RvD1 can be considered for further investigation of their therapeutic potential for treating ENDO.

Topics: Animals; Anti-Inflammatory Agents; Capillary Permeability; Disease Models, Animal; Docosahexaenoic Acids; Endometriosis; Female; Hyperalgesia; Injections, Intraperitoneal; Injections, Intravenous; Pain Threshold; Rats, Sprague-Dawley; Severity of Illness Index; Vagina